25 years of maturation: A systematic review of RNAi in the clinic
IJ Corydon, BK Fabian-Jessing, TS Jakobsen… - … Therapy-Nucleic Acids, 2023 - cell.com
… Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related …
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients …
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients …
Improved nucleic acid therapy with advanced nanoscale biotechnology
Y Weng, Q Huang, C Li, Y Yang, X Wang, J Yu… - … Therapy-Nucleic Acids, 2020 - cell.com
… Meanwhile, more than 2,000 clinical trials of NA therapies are underway, and more NA
drugs are in the pipeline of biopharmaceutical companies. These data show us that the NA …
drugs are in the pipeline of biopharmaceutical companies. These data show us that the NA …
Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks
Z Yang, T Liu, X Ren, M Yang, C Tu, Z Li - Cell Cycle, 2022 - Taylor & Francis
… targeting, and miRNAs to silence STMN1 might be effective strategies to inhibit cell
division [Citation79–81]. Besides, a recent study showed that PAI-1 participates in the p53–miR-34a …
division [Citation79–81]. Besides, a recent study showed that PAI-1 participates in the p53–miR-34a …
Nucleic acid anticancer agents
S Samaddar, DH Thompson - Biomaterials for Cancer Therapeutics, 2020 - Elsevier
… STMN1 is a cytosolic protein with major promitotic responsibility that is … cancer cell survival
and proliferation [33], [34], [35]. Their Phase I study in superficial advanced refractory cancer …
and proliferation [33], [34], [35]. Their Phase I study in superficial advanced refractory cancer …
[HTML][HTML] In Situ Vaccine: Breaking the Traditional Vaccine Paradigm
Y Chu, B Liu - 2023 - intechopen.com
… In a Phase I study of OX40 agonist MOXR0916 administered … events (AEs) were Grade
1–2 and related to MOXR0916 … Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer. …
1–2 and related to MOXR0916 … Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer. …
Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression
S You, Z Luo, N Cheng, M Wu, Y Lai, F Wang… - Drug Delivery and …, 2023 - Springer
… In this study, we first found that circ_0058051, as a new oncogenic factor, can participate
in … gene therapy on cancer due to the lack of an efficacious target. In this study, our results …
in … gene therapy on cancer due to the lack of an efficacious target. In this study, our results …